Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ENSG00000289911 gene corresponds to a novel transcript classified as an RNA gene, specifically an antisense transcript to PTP4A1[5]. It is not annotated as protein-coding and its expression pattern, regulatory function, or implication in any disease or cellular pathway have not been characterized in available literature. Unlike PTP4A1, which encodes a protein tyrosine phosphatase involved in cell signaling and cancer, this antisense transcript has no known function or relevance as a drug target[1][5]. It is listed in gene databases as a predicted or hypothetical non-coding RNA. There is no evidence that it functions as a receptor, enzyme, transcription factor, or other classical drug target. If you are seeking information on the protein tyrosine phosphatase 4A1 (PTP4A1) itself, that is a distinct, well-characterized protein-coding gene with established roles in cancer biology[1][3], but ENSG00000289911 only refers to a non-coding, antisense transcript related to PTP4A1[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to PTP4A1 (ENSG00000289911).